Short Wave A new step toward ending 'the wrath of malaria'
Nov 2, 2021
Winter Okoth, a passionate malaria researcher from Kenya, shares her harrowing childhood experiences with the disease and its impact on children. She discusses the recent endorsement of MoSQUIRIX, the first malaria vaccine, explaining how even its modest efficacy can dramatically influence malaria control. Okoth emphasizes the importance of integrating this vaccine with traditional prevention methods like bed nets and community education to break the cycle of malaria. Her insights reveal a hopeful path forward in the fight against this deadly disease.
AI Snips
Chapters
Transcript
Episode notes
Winter's Malaria Experience
- Winter Okoth, a malaria researcher, experienced malaria many times growing up in Kenya.
- One severe instance during primary school involved her grandmother using boiled leaves to relieve symptoms.
First Malaria Vaccine Endorsed
- In October, WHO endorsed the first malaria vaccine, marking a significant step.
- This breakthrough is especially meaningful given the high child mortality rate from malaria.
Vaccine Efficacy
- The malaria vaccine has a 30% efficacy rate, which seems low compared to other vaccines.
- Despite this, it's a crucial starting point for combating a complex disease.